

Puja P Khanna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2521172/publications.pdf>

Version: 2024-02-01

27
papers

3,693
citations

394421

19
h-index

552781

26
g-index

27
all docs

27
docs citations

27
times ranked

3765
citing authors

#	ARTICLE	IF	CITATIONS
1	2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. <i>Arthritis Care and Research</i> , 2012, 64, 1431-1446.	3.4	1,268
2	2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1447-1461.	3.4	598
3	2020 American College of Rheumatology Guideline for the Management of Gout. <i>Arthritis Care and Research</i> , 2020, 72, 744-760.	3.4	420
4	Gout. <i>Nature Reviews Disease Primers</i> , 2019, 5, 69.	30.5	326
5	Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) Gastrointestinal Symptom Scales. <i>American Journal of Gastroenterology</i> , 2014, 109, 1804-1814.	0.4	190
6	Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. <i>Health and Quality of Life Outcomes</i> , 2012, 10, 117.	2.4	152
7	Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 811-820.	0.9	141
8	Patient-reported Outcomes in Chronic Gout: A Report from OMERACT 10. <i>Journal of Rheumatology</i> , 2011, 38, 1452-1457.	2.0	84
9	Treatment of acute gout: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 31-38.	3.4	73
10	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1592-1600.	0.9	72
11	Establishing clinical severity for PROMIS® measures in adult patients with rheumatic diseases. <i>Quality of Life Research</i> , 2018, 27, 755-764.	3.1	52
12	Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial. <i>Rheumatology</i> , 2010, 49, 955-959.	1.9	47
13	Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1186-1192.	2.3	36
14	Systemic Urate Deposition: An Unrecognized Complication of Gout?. <i>Journal of Clinical Medicine</i> , 2020, 9, 3204.	2.4	36
15	Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-blind, Placebo-controlled Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 1523-1532.	5.6	30
16	Evolution of management of gout. <i>Current Opinion in Rheumatology</i> , 2015, 27, 139-146.	4.3	26
17	Development of an Online Library of Patient-Reported Outcome Measures in Gastroenterology: The GI-PRO Database. <i>American Journal of Gastroenterology</i> , 2014, 109, 234-248.	0.4	25
18	A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift. <i>Postgraduate Medicine</i> , 2016, 128, 34-40.	2.0	25

#	ARTICLE	IF	CITATIONS
19	Health-related quality of life and treatment satisfaction in patients with gout: results from a cross-sectional study in a managed care setting. Patient Preference and Adherence, 2015, 9, 971.	1.8	24
20	Performance of Anti-Topoisomerase I Antibody Testing by Multiple-Bead, Enzyme-Linked Immunosorbent Assay and Immunodiffusion in a University Setting. Journal of Clinical Rheumatology, 2020, 26, 115-118.	0.9	18
21	Racial differences in health-related quality of life and functional ability in patients with gout. Rheumatology, 2017, 56, 103-112.	1.9	14
22	The impact of gout guidelines. Current Opinion in Rheumatology, 2015, 27, 225-230.	4.3	12
23	Performance of Gout Impact Scale in a longitudinal observational study of patients with gout. Rheumatology, 2016, 55, 982-990.	1.9	12
24	Evaluation of Proposed Criteria for Remission and Evidence-Based Development of Criteria for Complete Response in Patients With Chronic Refractory Gout. ACR Open Rheumatology, 2019, 1, 236-243.	2.1	7
25	Development and Pilot Testing of MyGoutCare. Journal of Clinical Rheumatology, 2020, 26, 320-326.	0.9	3
26	Gout: a patrician malady no more. Lancet Diabetes and Endocrinology,the, 2018, 6, 263-264.	11.4	2
27	Remission in Gout: Concepts From a Patient Perspective. Journal of Rheumatology, 2022, , jrheum.211285.	2.0	0